# Nucleic Acid Drugs Sector Canonical URL: https://biopharmsignal.com/sector/nucleic-acid-drugs Nucleic Acid Drugs includes companies developing RNA, DNA, antisense, siRNA, mRNA, or related therapeutic approaches. This category is useful for tracking businesses whose core assets rely on sequence-based medicines rather than traditional small molecules or antibodies. Companies currently grouped under Nucleic Acid Drugs: 14 ## Recent Sector News - 2026-08-27 20:30 EST — BNTX — [Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine](https://biopharmsignal.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine-fd7ed680) — Source: BioNTech - 2026-08-24 11:30 EST — ABUS — [Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share](https://biopharmsignal.com/news/ABUS/arbutus-commences-us-230-million-modified-dutch-auction-tender-offer-of-its-comm-9dbefa64) — Source: Arbutus - 2026-08-21 11:30 EST — ABUS — [Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer](https://biopharmsignal.com/news/ABUS/arbutus-announces-intent-to-repurchase-up-to-us-230-million-of-its-common-shares-05a0a891) — Source: Arbutus - 2026-08-20 09:30 EST — BNTX — [BioNTech präsentiert auf der WCLC 2026 Fortschritte ihrer spätklinischen Pipeline bei Lungenkrebs und erste globale Daten zur innovativen Behandlungskombination aus Pumitamig und Elfetabart Drozuntecan](https://biopharmsignal.com/news/BNTX/biontech-pr-sentiert-auf-der-wclc-2026-fortschritte-ihrer-sp-tklinischen-pipelin-8123819f) — Source: BioNTech - 2026-08-20 09:30 EST — BNTX — [BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026](https://biopharmsignal.com/news/BNTX/biontech-highlights-late-stage-lung-cancer-pipeline-momentum-and-first-global-da-e409d803) — Source: BioNTech - 2026-08-13 05:00 EST — PHAR — [Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older](https://biopharmsignal.com/news/PHAR/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-15d022ed) — Source: Pharming Group - 2026-08-12 11:30 EST — ABUS — [Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-second-quarter-2026-financial-results-and-provides-corporate-upd-59eeaa34) — Source: Arbutus - 2026-08-04 10:45 EST — BNTX — [BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2026 sowie Informationen zur Geschäftsentwicklung](https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-ergebnisse-f-r-das-zweite-quartal-2026-sowie-information-2f0be20d) — Source: BioNTech - 2026-08-04 10:45 EST — BNTX — [BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update](https://biopharmsignal.com/news/BNTX/biontech-announces-second-quarter-2026-financial-results-and-corporate-update-20d0ffe1) — Source: BioNTech - 2026-08-04 06:00 EST — PHAR — [Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-canaccord-genuity-46th-annual-growth-conference-89bea5c1) — Source: Pharming Group - 2026-08-03 09:00 EST — BNTX — [BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden](https://biopharmsignal.com/news/BNTX/biontech-ernennt-dr-guido-oelkers-zum-neuen-vorstandsvorsitzenden-ee848391) — Source: BioNTech - 2026-08-03 09:00 EST — BNTX — [BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer](https://biopharmsignal.com/news/BNTX/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-exe-ec8ad74b) — Source: BioNTech - 2026-07-30 05:00 EST — PHAR — [Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use](https://biopharmsignal.com/news/PHAR/pharming-reports-second-quarter-and-first-half-2026-financial-results-and-revise-5218552c) — Source: Pharming Group - 2026-07-29 20:30 EST — BNTX — [Europäische Kommission genehmigt Marktzulassung des an XFG angepassten COVID-19-Impfstoffs von Pfizer und BioNTech in der Europäischen Union](https://biopharmsignal.com/news/BNTX/europ-ische-kommission-genehmigt-marktzulassung-des-an-xfg-angepassten-covid-19--ca9e72a1) — Source: BioNTech - 2026-07-29 20:30 EST — BNTX — [European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union](https://biopharmsignal.com/news/BNTX/european-commission-authorizes-pfizer-and-biontech-xfg-adapted-covid-19-vaccine--2746d430) — Source: BioNTech - 2026-07-21 10:45 EST — BNTX — [BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt](https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-am-4-august-2026-ergebnisse-f-r-das-zweite-quartal-2026--87f9447b) — Source: BioNTech - 2026-07-21 10:45 EST — BNTX — [BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026](https://biopharmsignal.com/news/BNTX/biontech-to-report-second-quarter-2026-financial-results-and-corporate-update-on-aeeb45ba) — Source: BioNTech - 2026-07-16 11:30 EST — ABUS — [Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders](https://biopharmsignal.com/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-actions-against--c6198417) — Source: Arbutus - 2026-07-16 06:00 EST — PHAR — [Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-second-quarter-and-first-half-2026-financial-results-an-f222ee56) — Source: Pharming Group - 2026-06-04 05:00 EST — PHAR — [Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS](https://biopharmsignal.com/news/PHAR/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-5cf3429e) — Source: Pharming Group ## Companies - [ALNY](https://biopharmsignal.com/company/ALNY) — Alnylam Pharmaceuticals, Inc. - [ABUS](https://biopharmsignal.com/company/ABUS) — Arbutus - [BNTC](https://biopharmsignal.com/company/BNTC) — Benitec Biopharma - [BPTH](https://biopharmsignal.com/company/BPTH) — Bio-Path Holdings - [BNTX](https://biopharmsignal.com/company/BNTX) — BioNTech - [CAMX](https://biopharmsignal.com/company/CAMX) — Camurus - [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences - [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson - [MRNA](https://biopharmsignal.com/company/MRNA) — Moderna, Inc. - [PHAR](https://biopharmsignal.com/company/PHAR) — Pharming Group - [PHIO](https://biopharmsignal.com/company/PHIO) — Phio Pharmaceuticals - [RGLS](https://biopharmsignal.com/company/RGLS) — Regulus Therapeutics - [SLN](https://biopharmsignal.com/company/SLN) — Silence Therapeutics - [RNAZ](https://biopharmsignal.com/company/RNAZ) — TransCode Therapeutics, Inc.